➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Dow
McKinsey
Baxter
Merck
AstraZeneca

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AZD4547

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AZD4547?

AZD4547 is an investigational drug.

There have been 16 clinical trials for AZD4547. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.

The most common disease conditions in clinical trials are Lung Neoplasms, Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Southwest Oncology Group.

There are nineteen US patents protecting this investigational drug and one hundred and fifty-one international patents.

Recent Clinical Trials for AZD4547
TitleSponsorPhase
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerAstraZenecaPhase 1
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)National Cancer Institute (NCI)Phase 2
Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"Assistance Publique - Hôpitaux de ParisPhase 1/Phase 2

See all AZD4547 clinical trials

Clinical Trial Summary for AZD4547

Top disease conditions for AZD4547
Top clinical trial sponsors for AZD4547

See all AZD4547 clinical trials

US Patents for AZD4547

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD4547   Start Trial Methods for treating cancer by inhibiting FGFR3/TACC3 fusion protein Astellas Pharma Inc. (Tokyo, JP)   Start Trial
AZD4547   Start Trial Deuterated triazolopyridazine as a kinase modulator Janssen Pharmaceutica NV (Beerse, BE)   Start Trial
AZD4547   Start Trial Fusion proteins and methods thereof The Trustees of Columbia University in the City of New York (New York, NY)   Start Trial
AZD4547   Start Trial Compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD4547

Drugname Country Document Number Estimated Expiration Related US Patent
AZD4547 Australia AU2013228389 2032-03-08   Start Trial
AZD4547 Brazil BR112014021897 2032-03-08   Start Trial
AZD4547 Canada CA2865388 2032-03-08   Start Trial
AZD4547 China CN104379740 2032-03-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
McKinsey
Baxter
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.